Acta Scientific Veterinary Sciences (ASVS)(ISSN: 2582-3183)

Research Article Volume 2 Issue 9

Regression of Symptoms of Trypanosomosis in Mice Dosed Cotrimoxazole-Antivirt® {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3} Formulation

MCO Ezeibe*, MI Ezeja, CA Akpan, FIO Onyeachonam, ME Sanda, IJ Ogbonna, E Kalu, NU Njoku and MI Udobi

College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria

*Corresponding Author: MCO Ezeibe, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Received: July 29, 2020; Published: August 25, 2020

×

Abstract

Protozoa require Folic acid for replication and Cotrimoxazole inhibits synthesis of the B-vitamin. So, the drug could be effective for treatment of trypanosomosis (tropical protozoan disease of man and animals). To improve efficacy of such treatment on symptoms of the disease, a formulation of the medicine and The Medicinal synthetic Aluminum-magnesium silicate (Antivirt®) was used to treat mice. Cotrimoxazole improved (P ≤ 0.05) PCV, RBC and HB in uninfected mice (from 47.60 ± 0.51, 7.93 ± 0.09 and 15.87 ± 0.17 to 59.60 ± 0.51, 9.93 ± 0.09 and 19.93 ± 0.12) and in trypanosome-infected mice (from 34.75 ± 0.48, 5.79 ± 0.08 and 11.67 ± 0.14 to 37.67 ± 0.88, 6.28 ± 0.15 and 12.56 ± 0.29) but it worsened fever in trypanosome-infected mice (from rectal temperature: 36.30 ± 0.35 to 46.27 ± 0.79). Stabilizing the drug with Antivirt® reduced (P ≤ 0.05) that adverse effect (fever) from temperature of 46.27 ± 0.79 to 39.50 ± 0.29. Weight of the mice remained approximately (P ≥ 0.05) same in all the groups. Formulation of Cotrimoxazole (anti-protozoan) and Antivirt® could be a new medicine for trypanosomosis (sleeping sickness).

Keywords: Trypanosomes; Cotrimoxazole; Pyrogens; Trypanosomosis-symptoms (Fever, Anemia)

×

References

  1. Barret MP., et al. “Human African Trypanosomiasis: Pharmacological re-engagement with a neglected disease”. British Journal of Pharmacology 152 (2007): 1155-1171.
  2. Rashid A., et al. “Trypanosomiasis in dogs: A case report”. Iranian Journal of Arthropod-Borne Diseases 2.2 (2008): 48-51.
  3. Samdi SM., et al. “Impact of trypanosomosis on food security. Security in Nigeria: A review”. International Journal of Animal and Veterinary Advances 2.2 (2010): 47-50.
  4. Soulsby EJI Helminthes. “Arthropods and Protozoa of domesticated animals, 7th edition”. Balliere Tindall London (1982): 203-206.
  5. Abenga JN., et al. “Prevalence of trypanosomosis in trade cattle at slaughter in Kaduna”. Nigeria Journal of Parasitology 23 (2002): 107-110.
  6. Anene BM., et al. “Preliminary efficacy trial of Cymelersan in dogs and mice artificially infected with Trypanosoma brucei isolated from dogs in Nigeria”. Revue D’elevage Et De Medicine Veterinaire Des Pays Tropicaux 52 (1999): 123-128.
  7. Anene BM., et al. “A Diminazene-Resistant strain of Trypanosoma brucei isolated from a dog in cross resistant to Pentamidium in experimentally infected albino rats”. Parasitology 132 (2006): 127-133.
  8. Onyiah JA. “African animal trypanosomosis: An overview of the current status in Nigeria”. Tropical Veterinarian 155 (1997): 111-116.
  9. Oyewusi JA., et al. “The course of trypanosomiasis in laboratory rabbits following experimental infection, treatment and re-infection: haematological study”. European Journal of Scientific Research 42 (2010): 411-419.
  10. WHO. Control and surveillance of African trypanosomiasis. Report of WHO Expert Committee, World Health Organization Technical Report series (1998): 881.
  11. Kristjanson PM., et al. “Measuring the costs of African animal trypanosomosis, the potential benefits of control and returns to research”. Agricultural Systems 59 (1999): 79-98.
  12. Delespaux V and De Koning HP. “Drugs and drug resistance in African trypanosomiasis”. Drug Resist 10 (2007): 30-50.
  13. Goldberg E and Bishara J. “Contemporary unconventional clinical use of cotrimoxazole”. Clinical Microbiology and Infection 18.1 (2012): 8-17.
  14. Gleckman R., et al. “Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications”. Pharmacotherapy 1 (1981): 14.
  15. Hong YL., et al. “Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs”. Antimicrobial Agents and Chemotherapy 39 (1995): 1756.
  16. Bushby SRM. “Trimethoprim-sulfamethoxazole: in vitro microbiological aspects”. Journal of Infectious Diseases 128.3 (1973): S442-S462.
  17. Bushby SR and Hitchings GH. “Trimethoprim, a sulphonamide potentiator”. British Journal of Pharmacology 33.1 (1968): 72-90. 
  18. Böhni E. “Chemotherapeutic activity of the combination of trimethoprim and sulfamethoxazole in infections of mice”. Postgraduate Medical Journal 45 (1969): 18-21.
  19. Vanderbilt Report. “Technical Information: VEEGUM - The versatile ingredient for Pharmaceutical Formulations”. R.T. Vanderbilt Company Bulletin 91R. R.T. Vanderbilt Company Inc., Norwalk (2012).
  20. Brent W., et al. “What Do We Really Know about Antibiotics Pharmacodynamics?” Pharmcotherapy 21 (2001): 28-31. 
  21. Ezeibe MCO., et al. “Effect of Aluminum Magnesium Silicate on anticoccidial activity of sulphadimidine”. Tropical Veterinarian 29 (2011): 41-44.
  22. Suni L., et al. “Immunostimulation by Silica Particles and the Development of Autoimmune Dysregulation”. In Tech Open (2014).
  23. Ezeibe MCO., et al. “Adjuvant effect of a synthetic Aluminium-Magnesium Silicate on chloroquine phosphate, against plasmodium berghei”. Nature Proceedings (2012).
  24. Ezeibe MCO., et al. “Aluminium-Magnesium Silicate enhances antibacterial activity of Ampicillin trihydrate, against Salmonella. Gallinarum”. Nature Proceedings (2012).
  25. Ezeibe. “Medicinal synthetic Aluminum-magnesium silicate (Nanoparticles)-Antiviral agent and adjuvant to chemotherapeutics”. Federal Republic of Nigeria Patents and Designs.
  26. Ezeibe MCO., et al. “Restoring efficacy to cotrimoxazole against resistant Salmonella pullorum with Medicinal synthetic Aluminum-magnesium silicate: Al4 (SiO4)3 + 3Mg2SiO4 →2Al2 Mg3 (SiO4)3]”. Health 11.9 (2019): 1162-1168.
  27. Akpan CA. “Prevalence of Trypanosomes in Cattle, Sheep and Goats in Rivers state and Abia state Nigeria and Exploitation of anti-Foliate effect of Cotrimoxazole for treatment of Trypanosomosis”. PhD Dissertation, Michael Okpara University of Agriculture, Umudike, Nigeria (2020).
×

Citation

Citation: MCO Ezeibe.,et al. “Regression of Symptoms of Trypanosomosis in Mice Dosed Cotrimoxazole-Antivirt® {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3} Formulation”.Acta Scientific Medical Sciences 2.9 (2020): 23-28.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor0.518

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US